Danaher Acquires Masimo in $5.7 Billion Deal – Transforming Patient Monitoring & Healthcare Tech

On February 2026, Danaher Corporation (NYSE: DHR) announced the successful completion of its $5.7 billion acquisition of Masimo Corporation (NASDAQ: MASI), a global medical technology company known for its pioneering noninvasive monitoring solutions.The deal, first announced in late 2025, brings Masimo’s industry-leading technologies — including Signal Extraction Technology (SET®) pulse oximetry, rainbow® Pulse CO-Oximetry, SedLine® brain function monitoring, and the growing W1™ and Freedom™ consumer health wearables — into Danaher’s diagnostics and life sciences portfolio.Key Deal DetailsPurchase price: $5.7 billion (all-cash transaction) Structure: Danaher acquired all outstanding shares of Masimo at $140 per share. Closing: Completed after receiving all required regulatory approvals (including Hart-Scott-Rodino clearance). Expected synergies: $100–$150 million in annual cost synergies within 2–3 years through supply chain optimization, shared R&D, and commercial integration. Strategic RationaleComplementary portfolios — Masimo’s noninvasive monitoring strengthens Danaher’s diagnostics segment (Cepheid, Beckman Coulter, Leica Biosystems) and expands into high-growth areas like continuous patient monitoring and consumer health. Innovation accelerator — Masimo’s AI-driven algorithms and wearable tech will integrate with Danaher’s existing platforms to create next-generation diagnostic and monitoring solutions. Market expansion — Masimo’s strong presence in hospitals, ambulatory settings, and direct-to-consumer channels complements Danaher’s global reach. Market & Industry ReactionDanaher stock: Rose ~3–5% post-closing announcement on synergy expectations. Masimo shareholders: Received a 35–40% premium over pre-announcement price. Analysts: Bullish — see the deal as a smart move for Danaher to diversify beyond traditional diagnostics into real-time patient monitoring and digital health. CEO Rainer M. Blair (Danaher): “Masimo’s breakthrough technologies and talented team are a perfect fit for Danaher. Together, we’ll accelerate innovation in patient care and create significant value for customers and shareholders.”At digital8hub.com, we track healthcare M&A, medical device deals, diagnostics industry, AI in healthcare, and more. Looking for analysis of Danaher’s portfolio post-Masimo, patient monitoring trends, or competitive landscape vs. Medtronic, Philips, GE HealthCare? Check our business and health-tech sections.Danaher + Masimo = a powerful new force in healthcare innovation. The patient monitoring space just got a lot more interesting.